{"id":170020,"date":"2023-08-19T07:22:49","date_gmt":"2023-08-19T12:22:49","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/08\/regenerons-antibody-gets-fda-approval-for-ultra-rare-hereditary-disease"},"modified":"2023-08-19T07:22:49","modified_gmt":"2023-08-19T12:22:49","slug":"regenerons-antibody-gets-fda-approval-for-ultra-rare-hereditary-disease","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/08\/regenerons-antibody-gets-fda-approval-for-ultra-rare-hereditary-disease","title":{"rendered":"Regeneron\u2019s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/regenerons-antibody-gets-fda-approval-for-ultra-rare-hereditary-disease.jpg\"><\/a><\/p>\n<p>The FDA on Friday approved Regeneron Pharmaceuticals\u2019 Veopoz (pozelimab-bbfg), the first and only treatment indicated specifically for CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, according to the company.<\/p>\n<p>A fully human monoclonal antibody, Veopoz is approved for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE, an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms.<\/p>\n<p>- CHAPLE\u2014which stands for complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy\u2014is an inherited immune disease that causes the complement system (the part of your immune system that defends the body against injury and foreign invaders like bacteria and viruses) to become overactive.-FDA.<\/p>\n<hr>\n<p>The regulator\u2019s greenlight on Friday for Regeneron Pharmaceuticals\u2019 monoclonal antibody Veopoz (pozelimab-bbfg) makes it the first and only treatment indicated for children and adults with CHAPLE disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA on Friday approved Regeneron Pharmaceuticals\u2019 Veopoz (pozelimab-bbfg), the first and only treatment indicated specifically for CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, according to the company. A fully human monoclonal antibody, Veopoz is approved for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE, an ultra-rare [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-170020","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/170020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=170020"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/170020\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=170020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=170020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=170020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}